Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
Status:
Not yet recruiting
Trial end date:
2025-05-31
Target enrollment:
Participant gender:
Summary
This is a single arm, multi center, exploratory clinical study to evaluate the efficacy and
safety of fluzoparide combined with alpatinib as neoadjuvant therapy in patients with BRCA1/2
gene mutation or HRD gene mutation, advanced ovarian cancer, primary peritoneal cancer,
fallopian tube cancer ((FIGO stage III or IV), who can not achieve R0 tumor reduction surgery
after imaging evaluation or laparoscopic evaluation .